First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease

dc.creatorRamirez, Juan C.
dc.creatorParrado, Rudy
dc.creatorSulleiro, Elena
dc.creatorde la Barra, Anabelle
dc.creatorRodriguez, Marcelo
dc.creatorVillarroel, Sandro
dc.creatorIrazu, Lucía
dc.creatorAlonso-Vega, Cristina
dc.creatorAlves, Fabiana
dc.creatorCurto, María A
dc.creatorGarcia, Lineth
dc.creatorOrtiz, Lourdes
dc.creatorTorrico, Faustino
dc.creatorGascon, Joaquim
dc.creatorFlevaud, Laurence
dc.creatorMolina, Israel
dc.creatorRibeiro, Isabela
dc.creatorSchijman, Alejandro G.
dc.date2020-12-18T16:01:50Z
dc.date2020-12-18T16:01:50Z
dc.date2017-12-27
dc.date.accessioned2023-08-29T20:08:01Z
dc.date.available2023-08-29T20:08:01Z
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/1947
dc.identifier10.1371/journal.pone.0188550
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8519959
dc.descriptionFil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
dc.descriptionFil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
dc.descriptionFil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
dc.descriptionFil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
dc.descriptionFil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
dc.descriptionFil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
dc.descriptionFil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
dc.descriptionFil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.
dc.descriptionFil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.
dc.descriptionFil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
dc.descriptionFil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
dc.descriptionFil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.
dc.descriptionFil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.
dc.descriptionFil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.
dc.descriptionFil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.
dc.descriptionFil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
dc.descriptionFil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.
dc.descriptionFil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
dc.descriptionReal-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.
dc.formatpdf
dc.languageen
dc.publisherPublic Library of Science
dc.relation#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.relationdatasets
dc.relationPloS one
dc.rightsopen
dc.sourcePLoS One 2017; 12(11):e0188550
dc.subjectEnfermedad de Chagas
dc.subjectHumanos
dc.subjectMonitoreo Fisiológico
dc.subjectNitroimidazoles
dc.subjectReacción en Cadena en Tiempo Real de la Polimerasa
dc.subjectTriazoles
dc.subjectTripanocidas
dc.titleFirst external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
dc.typeArtículo


Este ítem pertenece a la siguiente institución